# OnCo record nct06008093 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06008093/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06008093", "NCT06008093" ;
  schema:name "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS"@en ;
  schema:alternateName "TRITON"@en ;
  schema:description "A phase 2 trial of Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06008093/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06008093> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-04-04" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .